Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Comment by gonefishing2022 on Oct 28, 2021 6:40am
Not Much Posting,Everyone just checking for the halt or the News any Day now
Comment by consultant99 on Oct 28, 2021 11:27am
It is sad that shareholders have to beg for scraps of information from a company that has stopped communicating since the disasterous funding of the Phase 2 trial.  There is no share price volatility. There are few and far between press releases. The Phase 2 trial is moving along at a snails pace and apparently there is no progress worth sharing on the development front for the other cancer ...more  
Comment by fredgoodwinson on Oct 28, 2021 1:14pm
Not sad - a ******* disgrace.
Comment by fredgoodwinson on Oct 28, 2021 6:06pm
Not asking for anyone to answer the phone - just for the CEO to do the job that he`s being paid for. Won`t succumb Stockholm Syndrome style to gratefully accepting these poorly formatted ambiguous and ever-receding Quarterlies as any sort of substitute for the way that we were once decently informed and particularly not grateful that the precise date of the next one has apparently been ...more  
Comment by Johnandrose22 on Oct 28, 2021 6:51pm
Perfectly articulated...thank you.
Comment by socksnblonds642 on Oct 28, 2021 2:17pm
Has anyone received a call back from investor relations? I think others have tried recently also. Crickets!
Comment by Gooseybear on Oct 28, 2021 4:08pm
It could be because TLT got rid of several of them a while back to save money.
Comment by skys1 on Oct 28, 2021 7:43pm
Yes I do get responses however, I agree that the Company could do a much better job of keeping the share holders informed of and up to date of Company progress.
Comment by Longholder99 on Oct 28, 2021 3:23pm
You want them to pay for the trial or pay someone to answer the phone for antsy shareholders and telemarketers. Info come when it comes. Just my opinion..
Comment by socksnblonds642 on Oct 28, 2021 3:46pm
https://m.youtube.com/watch?v=E7NdrkKD8Vk
Comment by CancerSlayer on Oct 28, 2021 5:37pm
  Yep, simply a waiting game for enough data that would support a BTD...just 3 more patients is the goal/hope.  I'm just as eagerly awaiting news on the vaccine front.  This could be an even bigger news event.  However, my guess is such news will likely take significantly longer to come by.  I'd expect a more extended timeline if they are in the process of ...more  
Comment by CancerSlayer on Oct 28, 2021 6:13pm
  Immunostimulatory silica nanoparticle boosts innate immunity in brain tumors† Peter A. Bielecki,‡ab   Morgan E. Lorkowski,‡ab   Wyatt M. Becicka,‡a   Prabhani U. Atukorale,ab   Taylor J. Moon,a   Yahan Zhang,a   Michelle Wiese,a   Gil Covarrubias,ab  Shruthi ...more  
Comment by BlueFranky on Oct 28, 2021 6:23pm
Cancer Slayer... Can't thank you enough for your input on this board
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250